Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Castle Biosciences (Nasdaq:CSTL) announced that executive management will present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. ET. A live audio webcast and replay will be accessible via the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – CSTL
In the May 13 session, CSTL declined 2.58%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Neutral | -22.3% | Reported Q1 2026 results and raised full-year revenue guidance range. |
| May 05 | Advocacy initiatives | Positive | -3.6% | Supported nationwide advocacy, screenings and education for Skin Cancer Awareness Month. |
| May 04 | Clinical data update | Positive | +2.9% | Presented Mayo Clinic data showing TissueCypher improves Barrett’s esophagus risk management. |
| Apr 21 | Upcoming data presentations | Positive | -2.3% | Announced DecisionDx-Melanoma data presentations at EADO and ACMS meetings. |
| Apr 15 | Earnings date notice | Neutral | +1.0% | Scheduled Q1 2026 earnings release and webcast details for May 6. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several divergences where positive or neutral news (advocacy initiatives, data previews, earnings-date notices) saw negative or muted follow-through, while one strong clinical data update aligned with a positive move.
Over the last month, Castle Biosciences has issued earnings, clinical, advocacy and logistics updates. Q1 2026 results on May 6 featured $83.7M revenue and raised 2026 guidance to $345–355M, yet shares fell 22.26%. New data for TissueCypher at DDW 2026 on May 4 improved risk stratification and coincided with a 2.86% gain. Advocacy and melanoma data announcements in late April and early May saw small negative reactions. Today’s conference appearance fits into this cadence of ongoing visibility efforts rather than a discrete financial or clinical catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website or at this link. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-to-present-at-the-2026-jefferies-global-healthcare-conference-302770056.html
SOURCE Castle Biosciences, Inc.